Analyst consensus rating
Madrigal Pharmaceuticals Analyst Rating: Strong Buy
Direct answer
Madrigal Pharmaceuticals's consensus rating is Strong Buy.
18 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $685.78.
Forecast evidence checked October 17, 2026.
Get free Madrigal Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $449.74
- Average price target
- $685.78
- High price target
- $962.00
- Low price target
- $543.00
- Low target gap
- +20.7%
- Target upside
- +52.5%
- High target gap
- +113.9%
- Target range width
- 93.2%
- Consensus rating
- Strong Buy
- Analysts
- 18
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals has a verified Strong Buy consensus. The same dataset has an average price target of $685.78.
How far are Madrigal Pharmaceuticals's low and high targets from the recorded price?
The low target implies +20.7%, while the high target implies +113.9%.
How many analysts are included in Madrigal Pharmaceuticals's consensus?
The verified consensus includes 18 analysts.
How is Madrigal Pharmaceuticals's target upside or downside calculated?
The average target of $685.78 is divided by the recorded price of $449.74, then one is subtracted to produce +52.5%. This does not guarantee a future return.
When was Madrigal Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.